The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European pharmaceutical industry that is working to improve the drug development process and so accelerate the development of better, safer medicines for patients. IMI works by forging collaborative partnerships involving all stakeholders in medical research, including the pharmaceutical industry, universities, small and mediumsized enterprises (SMEs), patient groups, and regulatory agencies.
Since its creation in 2008, it has established itself as a pioneer of open collaboration, and the impressive results of IMI’s projects amply demonstrate the success of the public-private partnership model. In 2015, certain organisations and outlets have published articles and reports on the Innovative Medicines Initiative (IMI) which include a number of misconceptions and inaccuracies. This factsheet sets out and corrects some of the most commonly-repeated misunderstandings about IMI.
For more information, please read the following